Sunday 18 October 2026
Export ARCT’s income statement to Excel — free account
Arcturus Therapeutics Holdings Inc.
ARCT Healthcare Biotechnology
Arcturus Therapeutics Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $82.0 million, down 46.1% from fiscal 2024. In the quarter to June 2026, revenue fell 89.5%, EPS fell 147.1% and free cash flow fell 245.7%, each against the same quarter a year earlier.
10.34
0.93
−8.25%
Follow ARCT
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 1 | 4 | 4 | 1 | 6 | 3 | 3 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 49.12 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 0.00 | 2.90 | 6.31 | 92.34 | 78.81 | 2.14 | 5.28 | 3.01 | 2.05 |
Altman Z-Score |
1.79 | 0.69 | (1.00) | 0.18 | 6.77 | 1.49 | 1.73 | 2.78 | 1.20 | (0.61) |
Altman Z″-Score (non-manufacturers) |
(1.53) | 4.17 | (1.82) | (0.22) | 8.98 | (0.23) | 3.34 | 2.57 | 0.92 | 0.82 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.20 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | (4.96) | 4.47 | (1.13) | (2.83) | (3.07) | 11.77 | 9.44 | (3.62) | (1.29) |
P/Operating CF |
2.54 | 4.93 | (7.91) | (17.40) | (132.82) | (22.92) | 2.76 | (1,400.83) | (1,613.35) | (10.35) |
P/B ratio |
19.93 | 0.73 | 3.34 | 5.09 | 2.22 | 4.27 | 1.63 | 3.16 | 1.90 | 0.78 |
Price to Tangible BV |
19.93 | 0.73 | 3.34 | 5.09 | 2.22 | 4.27 | 1.63 | 3.16 | 1.90 | 0.78 |
EV/Sales |
0.00 | 0.00 | 1.20 | 3.61 | 45.40 | 53.94 | 0.68 | 3.69 | 1.62 | 0.15 |
EV/EBITDA |
0.00 | 2.37 | 0.00 | 0.00 | 0.00 | 0.00 | 10.26 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(8.12) | 52.05 | (0.91) | (11.63) | (10.10) | (4.94) | 4.40 | (33.97) | (4.13) | (0.17) |
EV/FCF |
(6.54) | 35.10 | (0.85) | (10.32) | (9.71) | (4.81) | 5.79 | (29.27) | (4.09) | (0.17) |
Quick Ratio |
1.37 | 4.46 | 3.28 | 3.45 | 9.39 | 3.76 | 3.11 | 4.62 | 4.52 | 6.50 |
Current Ratio |
1.41 | 4.61 | 3.33 | 3.48 | 9.45 | 3.81 | 3.18 | 4.72 | 4.67 | 6.64 |
Net Debt/EBITDA |
11.63 | 4.83 | 1.26 | 2.24 | 6.34 | 1.52 | (24.17) | 4.61 | 3.17 | 3.15 |
Debt/Assets |
0.97% | 0.00% | 22.42% | 19.26% | 3.17% | 16.07% | 13.47% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.08 | 0.00 | 0.73 | 0.61 | 0.04 | 0.28 | 0.22 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.48 | 0.40 | 0.33 | 0.33 | 0.03 | 0.03 | 0.49 | 0.38 | 0.39 | 0.27 |
Operating CF/Net income |
1.82 | 0.04 | 0.95 | 0.25 | 0.59 | 0.66 | 3.42 | 0.61 | 0.74 | 1.13 |
Capex/Depreciation |
(2.34) | (0.54) | (2.54) | (1.20) | (1.98) | (2.85) | (5.06) | (0.98) | (0.18) | (0.08) |
Interest Coverage |
(1.87) | (25.65) | 66.50 | (57.20) | (198.13) | (105.60) | 28.99 | 4.71 | 6.30 | 7.55 |
| (4.43%) | (61.64%) | (91.85%) | (131.82%) | (34.17%) | (65.20%) | 3.75% | (10.83%) | (31.16%) | (28.92%) | |
| (3.68%) | (33.16%) | (45.28%) | (41.14%) | (25.83%) | (46.86%) | 2.22% | (6.76%) | (20.93%) | (21.39%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(31.85%) | (26.67%) | (69.77%) | (46.99%) | (17.11%) | (71.45%) | 3.24% | (9.38%) | (32.37%) | (31.06%) |
Average Days of Receivables |
65.06 | 13.48 | 103.83 | 38.26 | 81.31 | 99.44 | 4.90 | 70.16 | 9.52 | 24.76 |
Research and Development Expense of Revenue |
87.99% | 122.46% | 107.80% | 161.82% | 606.42% | 1,405.94% | 71.72% | 115.19% | 128.13% | 136.79% |
Selling, General and Administrative Expense of Revenue |
16.92% | 58.26% | 130.65% | 60.91% | 243.39% | 335.39% | 22.36% | 31.70% | 34.68% | 56.17% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
1.47% | 16.69% | 7.99% | 9.53% | 70.91% | 233.96% | 14.86% | 20.77% | 24.94% | 30.97% |
Graham Net Nets |
0.01 | 1.32 | 0.25 | 0.14 | 0.44 | 0.22 | 0.51 | 0.27 | 0.44 | 1.10 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.84 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(40.29%) | (44.40%) | (47.80%) | (19.04%) | (7.81%) | (20.91%) | 2.04% | (3.38%) | (17.74%) | (38.83%) |
Free Cash Flow Yield |
(11.29%) | (2.77%) | (48.75%) | (5.54%) | (5.06%) | (14.21%) | 5.49% | (2.38%) | (13.18%) | (44.38%) |
Revenue per Share |
10.03 | 4.21 | 1.56 | 1.72 | 0.47 | 0.47 | 7.79 | 6.26 | 5.64 | 3.00 |
Operating CF per Share |
(1.41) | (0.15) | (2.06) | (0.53) | (2.11) | (5.13) | 1.21 | (0.68) | (2.21) | (2.71) |
Capex per Share |
(0.34) | (0.07) | (0.15) | (0.07) | (0.09) | (0.13) | (0.29) | (0.11) | (0.02) | (0.01) |
Free Cash Flow per Share |
(1.75) | (0.22) | (2.21) | (0.60) | (2.20) | (5.26) | 0.92 | (0.79) | (2.24) | (2.72) |
Cash per Share |
4.11 | 15.79 | 3.65 | 5.91 | 22.80 | 14.08 | 14.82 | 13.03 | 10.82 | 8.43 |
Shareholders Equity per Share |
0.78 | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | 10.22 | 10.46 | 8.93 | 7.81 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.78 | 10.95 | 1.35 | 2.14 | 19.53 | 8.67 | 10.22 | 10.46 | 8.93 | 7.81 |
Free Cash Flow |
(3.55) | (0.68) | (22.24) | (7.26) | (44.60) | (138.45) | 24.27 | (21.00) | (60.39) | (74.50) |
Working Capital |
3.60 | 39.83 | 29.25 | 52.97 | 418.27 | 279.42 | 276.35 | 304.60 | 240.49 | 205.07 |
Capital Expenditures |
(0.69) | (0.22) | (1.48) | (0.82) | (1.74) | (3.41) | (7.73) | (2.90) | (0.65) | (0.23) |
Net Current Asset Value |
0.17 | 32.64 | 11.27 | 17.94 | 387.89 | 214.36 | 223.26 | 235.70 | 202.89 | 184.28 |
EV/EBIT |
0.00 | 2.28 | 0.00 | 0.00 | 0.00 | 0.00 | 11.55 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.03 | 0.02 | 0.09 | 0.04 | 0.18 | 0.28 | 0.04 | 0.02 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 36.27 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.22 | 0.39 | 0.29 | 0.29 | 0.26 | 0.21 | 0.12 | 0.24 | 0.37 | 0.45 |
Cash ROIC |
(35.30%) | (0.83%) | (36.90%) | (6.43%) | (5.10%) | (20.92%) | 3.36% | (3.36%) | (11.33%) | (16.75%) |
Accounts Receivable Turnover |
10.04 | 6.32 | 6.35 | 6.24 | 4.43 | 4.50 | 67.20 | 9.58 | 8.45 | 17.20 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — | — | — | — | — | — |
Average Receivables |
2.03 | 2.06 | 2.48 | 3.33 | 2.15 | 2.75 | 3.07 | 17.41 | 18.02 | 4.77 |
Average Payables |
1.71 | 2.57 | 2.09 | 4.10 | 8.28 | 10.42 | 8.75 | 6.36 | 6.24 | 5.71 |
Average Assets |
42.71 | 32.88 | 48.11 | 63.17 | 279.30 | 434.64 | 421.60 | 439.89 | 386.74 | 307.61 |
Average Common Equity |
35.45 | 17.69 | 23.72 | 19.72 | 211.17 | 312.38 | 249.26 | 274.41 | 259.75 | 227.48 |
Columns are period end dates